Treatment consisted of repetitive cycles of interferon alfa and low-dose subcutaneous cytarabine.

The combination turned out to be no better than interferon alfa alone.

Modulation of FUra with interferon alfa has also shown some promise.

Shire said it has already filed a treatment protocol for its drug velaglucerase alfa.

Maintenance interferon alfa at the same dose was continued after the initial 20-week period.